31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded
study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of
CNM-Au8 in patients who have been diagnosed with Multiple Sclerosis (MS) within fifteen (15)
years of Screening. The primary endpoint for this study changes from baseline to week 12 in
CNS metabolic changes, based on 31P-MRSimaging.